Hillstream BioPharma changes name to Tharimmune, progress on acquiring TH104, plans Phase 1 trial in Q4

Canton Strategic Holdings, Inc.

Name change to Tharimmune effective Sep 25, 2023; new ticker THAR on Nasdaq.
Progressing towards acquiring clinical-stage asset TH104 with recently approved IND.
Expects to close TH104 acquisition in Q4 2023 and launch/complete Phase 1 PK trial by year-end.
TH104 targets chronic pruritis in primary biliary cholangitis; prior ex-US trials showed reliable bioavailability.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Canton Strategic Holdings, Inc.: Company changed its name from Hillstream BioPharma, Inc. to Tharimmune, Inc. via a Certificate of Amendment to its Certificate of Incorporation (effective 2023-09-25).

Change: charter amendment
Effective: 2023-09-25

Exact text from the filing

On September 21, 2023, Hillstream BioPharma, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to its Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware pursuant to which it changed its name to Tharimmune, Inc. effective as of September 25, 2023.

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

Canton Strategic Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-033591

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.